Howard Sofen (H Sofen)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Topics

Randomized Controlled Trial

Atopic Dermatitis

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

The Journal of dermatological treatment

The British journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard Bruce Warren, Carle F Paul, Jacek Cezary Szepietowski, Tsen Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British journal of dermatology 188 (2) (2023)
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard Bruce Warren, Carle F Paul, Jacek Cezary Szepietowski, Tsen Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British journal of dermatology 188 (2) (2023)
Abby S Van Voorhees, L Stein Gold, M Lebwohl, Bruce E Strober, Howard Sofen, Kim A Papp, J Bagel, Z Zhang, M Paris, Y Wang
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. The British journal of dermatology 185 (4) (2021)
Andrew Blauvelt, Kenneth B Gordon, Patricia Lee, Jerry Bagel, Howard Sofen, Benjamin Lockshin, Ahmed M Soliman, Ziqian Geng, Tianyu Zhan, Gabriela Alperovich, Linda F Stein Gold
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. The Journal of dermatological treatment (2021)
Richard Bruce Warren, Mark G Lebwohl, Howard Sofen, Vincent Piguet, Matthias Augustin, F Brock, null C Arendt, F Fierens, Andrew Blauvelt
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (12) (2021)
M Gooderham, B E Elewski, D M Pariser, Howard Sofen, A M Mendelsohn, S J Rozzo, Q Li
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (10) (2019)
A Blauvelt, Howard Sofen, K Papp, M Gooderham, S Tyring, Y Zhao, S Lowry, A Mendelsohn, J Parno, K Reich
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (12) (2019)
C Paul, L Guenther, H Torii, Howard Sofen, R Burge, C Y Lin, A Potts Bleakman, L Mallbris, Y Poulin
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (1) (2017)
A Blauvelt, K Reich, S Mehlis, F Vanaclocha, Howard Sofen, W Abramovits, Y Zhao, I Gilloteau, E Davenport, N Williams, A Guana, S Tyring
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (10) (2017)